Search Results

TGX-221 5 mg  | 98.98%

TargetMol

TGX-221, an effective, specific, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit, is utilized for cancer treatment.

More Information Supplier Page

TGX-221 50 mg  | 98.98%

TargetMol

TGX-221, an effective, specific, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit, is utilized for cancer treatment.

More Information Supplier Page

TGX-221 10 mg  | 98.98%

TargetMol

TGX-221, an effective, specific, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit, is utilized for cancer treatment.

More Information Supplier Page

Taladegib 2 mg  | 98.75%

TargetMol

Taladegib is an orally bioavailable small molecule antagonist of the Hedgehog (Hh)-ligand cell surface receptor smoothened (Smo) with potential antineoplastic activity.

More Information Supplier Page

Taladegib 50 mg  | 98.75%

TargetMol

Taladegib is an orally bioavailable small molecule antagonist of the Hedgehog (Hh)-ligand cell surface receptor smoothened (Smo) with potential antineoplastic activity.

More Information Supplier Page